This invention relates to new propanolamine derivatives or salts thereof represented by the following formula I: Wherein each symbol is as defined in the specification or salts thereof which have gut selective sympathomimetic, anti-ulcerous, anti-pancreatitis, lipolytic, anti-urinary incontinence and anti-pollakiuria activities, to processes for the preparation thereof, to a pharmaceutical composition comprising the same and to a method for the prevention and/or treatment diseases indicated in the specification to a human being or an animal.

Claims

39 · 39 independent · depth 1

39 granted claims

›1.independentA method for the prophylactic and/or therapeutic treatment of dysuria that comprises:

›2.independentThe method of claim 1, comprising administering the compound of formula (IV) or a salt thereof.

›3.independentThe method of claim 1 comprising administering the compound of formula (V) or a salt thereof.

›4.independentThe method of claim 1, comprising administering the compound of formula (VI) or a salt thereof.

›5.independentThe method of claim 1, comprising administering the compound of formula (VII) or a salt, ester or amide thereof.

›6.independentThe method of claim 1, comprising administering the compound of formula (VIII) or a salt thereof.

›7.independentThe method of claim 1 wherein said compound is in the form of a prodrug.

›8.independentA method for the prophylactic and/or the therapeutic treatment of pollakiuria or urinary incontinence comprising administering to a subject in need th…

›9.independentA method for the prophylactic and/or the therapeutic treatment of nervous pollakiuria, neurogenic bladder dysfunction, nocturia, unstable bladder, cys…

›10.independentA commercial package comprising:

›11.independentAn article of manufacture comprising:

›12.independentThe method of claim 1, comprising treating a subject having dysuria.

›13.independentThe method of claim 1, comprising treating a subject having pollakiuria.

›14.independentThe method of claim 1, comprising treating a subject having urinary incontinence.

›15.independentThe method of claim 1, comprising treating a subject having neurogenic bladder dysfunction.

›16.independentThe method of claim 1, comprising treating a subject having nervous pollakiuria.

›17.independentThe method of claim 1, comprising treating a subject having nocturia.

›18.independentThe method of claim 1, comprising treating a subject having an unstable bladder.

›19.independentThe method of claim 1, comprising treating a subject having cystospasm.

›20.independentThe method of claim 1, comprising treating a subject having chronic cystitis.

›21.independentThe method of claim 1, comprising treating a subject having chronic prostatitis.

›22.independentThe method of claim 1, comprising treating a subject having overflow incontinence.

›23.independentThe method of claim 1, comprising treating a subject having passive incontinence.

›24.independentThe method of claim 1, comprising treating a subject having reflux incontinence.

›25.independentThe method of claim 1, comprising treating a subject having urge incontinence.

›26.independentThe method of claim 1 comprising treating a subject having urinary stress incontinence.

›27.independentA compound of the general formula (I):

›28.independentThe compound of claim 27, wherein

›29.independentThe compound of claim 28, wherein

›30.independentA process for preparing a compound of claim 27, or a salt thereof, which comprises,

›31.independentA pharmaceutical composition which comprises the compound of claim 27, or a pharmaceutically acceptable salt thereof in admixture with a pharmaceutica…

›32.independentA method for making a pharmaceutical composition or a medicament comprising admixing the compound of claim 27 or a pharmaceutically acceptable salt th…

›33.independentA compound of claim 27 a pharmaceutically acceptable salt thereof in the form of a tablet, pellet, troche, capsule, suppository, cream, ointment, aero…

›34.independentA method for the prophylactic and/or the therapeutic treatment of pollakiuria or urinary incontinence which comprises administering an effective amoun…

›35.independentA method for agonizing a 3 adrenergic receptor comprising contacting said receptor with the compound of claim 27.

›36.independentA method for inducing gut-selective sympathomimetic activity comprising administering an effective amount of the compound of claim 27 to a subject in …

›37.independentA method for the prophylactic and/or the therapeutic treatment of a gastrointestinal disorder comprising administering an effective amount of the comp…

›38.independentA method for the prophylactic and/or the therapeutic treatment of an ulcer or pancreatitis comprising administering an effective amount of the compoun…

›39.independentA method for inducing lypolysis comprising administering an effective amount of the compound of claim 27 or a pharmaceutically acceptable salt thereof…

Classifications

71 codes

IPC · International Patent Classification

Section A — Human necessities

A61K3/154

USPC · US Patent Classification

514/222.5514/539546/207514/541514/385546/146514/577514/403546/168548/556548/262.4548/254514/382514/475548/131514/534548/511548/530514/311546/324514/319548/566514/471514/617548/492544/386514/255514/468546/205514/307548/503514/428544/67514/562514/443546/176549/407514/357549/58514/561544/358546/334544/159514/231.2544/283514/223.8546/152514/415514/459548/267.2546/139544/398544/402514/237.8548/356.1546/206544/162544/8548/510548/493548/128514/383548/504548/160514/563546/149548/252546/314549/405514/259

Claim changes

Soon

Coming soonHow the claims changed between publication and grant

See which claims were amended, added or cancelled during examination, with every added and removed word marked.

AmendedAddedCancelledUnchanged

The published claims of this patent are not paired with the granted ones in what we hold.

File wrapper

⤢ drag to zoom

USPTOApplicanthover for detail · click to open

Pendency

1.7 y

614 days filing → grant

Office actions

non-final + final

Responses

1 RCE

Interviews

examiner interview summaries

Examiner

Alan L. Rotman

art unit —

Law firm

Law firm · Log in to unlock

Citations: 9 back · 0 forward

See the full prosecution history — every USPTO and applicant action on this file, in order.

Term & fees

See the term timeline — pendency span, in-force span, the maintenance fees paid and both computed expiry dates.

Priority chain

1 priority documents

›Priority documents — 1

Type	Document	Date
related publication	US 20020120148 A1	29 Aug 2002

Validity challenges

See the validity challenges on record — reexaminations, IPRs and PGRs, with their institution decisions and outcomes.

Citations

See every patent this one cites and every patent that cites it back — publication, assignee, and how each one was found.